Absci

Integrated Drug Creation

AI-native antibody drug creation platform combining Origin-1 generative design model with lab-in-the-loop wet lab validation; supports de novo antibody design, multi-parametric lead optimization, and reverse immunology; applicable across oncology, immunology, inflammation, and other therapeutic areas with significant unmet medical need

Origin-1

De novo full-length monoclonal antibody design platform targeting zero-prior epitopes; generates epitope-specific, atomically accurate binders with functional potency; validated against four targets including COL6A3 and AZGP1 by cryo-EM; feeds into Integrated Drug Creation platform

Integrated Drug Creation · AMD

AI-native integrated drug creation platform combining Origin-1 generative design model with lab-in-the-loop rapid validation; supports de novo antibody design, multi-parametric lead optimization, and reverse immunology across oncology, immunology, and inflammation disease areas.

Origin

Generative AI platform for de novo antibody design; enables design of therapeutic candidates against challenging targets including prolactin receptor biology across multiple therapeutic areas

Targets: PRLR

ATLAS

Absci's drug discovery and design platform referenced in forward-looking statements alongside the company's generative AI approach

AbsciDesign

De novo AI antibody design platform using structure and sequence inputs to generate and experimentally validate therapeutic antibody candidates; focus areas include antibody-based therapeutics across immunology, inflammation, and metabolism